KPV vs LL-37

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

KPV and LL-37 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares KPV and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

KPVLL-37
CategoryPain ManagementPain Management
Regulatory status (US)Compounding (Rx) — Apr 2026Compounding (Rx) — Apr 2026
Typical dosage500-1000 mcg2-5 mg
Frequencydailytwice weekly
Reported benefitsInflammation reduction, pain relief, gut-related pain supportInflammation-related pain relief, infection-related pain support
Reported side effectsVery well-toleratedGenerally safe

Key differences

Primary use. KPV is categorised under Pain Management, while LL-37 falls under Pain Management. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. KPV: not FDA-approved; compounding permitted with a prescription as of April 2026. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.

Dosing. KPV is typically dosed at 500-1000 mcg (daily). LL-37 is typically dosed at 2-5 mg (twice weekly).

Can you stack them?

Some protocols combine peptides, but stacking KPV and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between KPV and LL-37?
KPV and LL-37 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status. KPV is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
What is KPV used for?
Anti-inflammatory pain relief.
What is LL-37 used for?
Inflammatory pain modulation.
Can you take KPV and LL-37 together?
Some users combine peptides within a single protocol, but stacking KPV and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is KPV or LL-37 FDA-approved?
KPV is not FDA-approved; compounding permitted with a prescription (as of April 2026). LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).

Read the full articles

  • KPV — full monograph: mechanism, research, dosing & references
  • LL-37 — full monograph: mechanism, research, dosing & references

More Pain Management comparisons

← All peptide comparisons